Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

“Notably, the 100 mg dose appears to be outpacing the 100 mg dose of amycretin, which achieved about a 5% placebo-adjusted weight loss in four weeks,” Hsieh wrote. Novo Nordisk stock fell ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Similarly, successful trials for CagriSema or oral amycretin could provide Novo Nordisk with next-generation products to drive growth beyond its current portfolio. Positive data could also support ...